Hepatic inflammation pathway

The hepatic inflammation pathway is a complex biological process characterized by the activation of the liver's innate immune system in response to stressors such as lipotoxicity, viral pathogens, or ethanol (Source: PubMed, PMID: 30214132). Central to this pathway is the activation of Kupffer cells and the subsequent release of pro-inflammatory cytokines, including Tumor Necrosis Factor-alpha (TNF-alpha) and Interleukin-6 (IL-6), which drive the recruitment of neutrophils and monocytes (Source: NIH, StatPearls). These inflammatory signals often activate the NF-kappaB and JNK signaling cascades, which not only promote cell death but also trigger hepatic stellate cells to transition into a myofibroblast-like phenotype, leading to excessive extracellular matrix deposition and fibrosis (Source: Wikipedia, Hepatic Stellate Cell). Chronic activation of the hepatic inflammation pathway is a primary driver of progression from simple steatosis to non-alcoholic steatohepatitis (NASH) and eventually to cirrhosis or hepatocellular carcinoma (Source: Nature Reviews Gastroenterology & Hepatology). Therapeutic targeting of this pathway involves a variety of approaches, including the use of FXR agonists like obeticholic acid to reduce bile acid-induced inflammation or chemokine receptor antagonists like cenicriviroc to block immune cell infiltration (Source: PubChem).

Other names

Liver inflammation pathwayHepatic inflammatory responseIntrahepatic inflammatory cascade

Modulation of the inflammatory cascade through the inhibition of pro-inflammatory cytokines, antagonism of chemokine receptors to prevent leukocyte infiltration, or activation of nuclear receptors that regulate metabolic and inflammatory gene expression.